ERBB3 and breast carcinoma: Since the expression level of HER2 is an established criterion to predict prognosis and drug response of breast cancer [36, 37], the interaction between FRET efficiency (reflecting HER2-HER3 dimer formation) and protein expression of HER2 using standard IHC scoring system was tested.